Psycho-cognitive assessment and quality of life in older adults with chronic obstructive pulmonary disease-carrying the rs4713916 gene polymorphism (G/A) of gene FKBP5 and response to pulmonary rehabilitation: a proof of concept study.
Journal
Psychiatric genetics
ISSN: 1473-5873
Titre abrégé: Psychiatr Genet
Pays: England
ID NLM: 9106748
Informations de publication
Date de publication:
01 06 2022
01 06 2022
Historique:
pubmed:
2
2
2022
medline:
18
5
2022
entrez:
1
2
2022
Statut:
ppublish
Résumé
Chronic obstructive pulmonary disease (COPD) is characterized by pulmonary and extra-pulmonary multi-morbidity including depression, anxiety and cognitive disorders. Several studies investigated the association of the FKBP5 gene polymorphisms with susceptibility to anxiety, depression, and behavioral disorders. The FKBP5 gene codifies the FKBP51 protein which modulates the glucocorticoid receptor in the adaptive stress response. Genetic variants of the FKBP5 gene have been associated to a higher risk of developing mental disorders. We analyzed the association of genetic variants and stress exposure investigating the susceptibility to psychological distress and the impact on cognitive balance and quality of life (QoL) of COPD patients carrying the rs4713916 polymorphism (G/A) and we examined its association, with COPD rehabilitative outcomes. A pilot study evaluated cognitive, psychological, clinical alterations/disorders, QoL, and coping strategies in 70 older adults with COPD, undergoing pulmonary rehabilitation, stratified according to the FKBP5 rs4713916 genotype (GG or GA). Carriers of rs4713916 polymorphisms (G/A) show better cognitive performances, a higher degree of independence in the daily living activities, better QoL, no presence of depressive mood and anxiety symptoms, no family history of psychiatric disorders, more ability to cope with stressors by avoiding emotions but demanding emotional support, and lesser use of anti-anxiety, anti-depressant, anti-psychotic, hypnotic-sedative drugs. No difference was found in the number of comorbidities. These results offer valuable insights into the role of FKBP5 in the complex network of mechanisms associated to clinical, psychological and behavioral features of COPD patients.
Identifiants
pubmed: 35102127
doi: 10.1097/YPG.0000000000000308
pii: 00041444-202206000-00003
doi:
Substances chimiques
Tacrolimus Binding Proteins
EC 5.2.1.-
tacrolimus binding protein 5
EC 5.2.1.8
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
116-124Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Références
GOLD. (2019). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease 2019. Report and strategies [Online]. https://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-v1.7-FINAL-14Nov2018-WMS.pdf . [Accessed].
ASSOCIATION, A. P. (2013). Diagnostic and statistical manual of mental disorders (5th edition). American Psychiatric Association; Diagnostic and Statistical Manual of Mental Disorders (DSM-5).
Atlantis E, Fahey P, Cochrane B, Smith S. (2013). Bidirectional associations between clinically relevant depression or anxiety and COPD: a systematic review and meta-analysis. Chest 144:766–777.
Augustin IML, Wouters EFM. (2017). Process of pulmonary rehabilitation and program organization. J Card Pulm Rehabil 1:109.
Beck AT, Steer R, Brown GK. (1996). Manual for the Beck Depression Inventory-II. San Antonio, TX: Psychological Corporation.
Binder EB. (2009). The role of FKBP5, a co-chaperone of the glucocorticoid receptor in the pathogenesis and therapy of affective and anxiety disorders. Psychoneuroendocrinology 34(Suppl 1):S186–S195.
Blakemore A, Dickens C, Guthrie E, Bower P, Kontopantelis E, Afzal C, Coventry PA. (2014). Depression and anxiety predict health-related quality of life in chronic obstructive pulmonary disease: systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis 9:501–512.
Brazier J. (1993). The SF-36 health survey questionnaire–a tool for economists. Health Econ 2:213–215.
Caffarra P, Vezzadini G, Dieci F, Zonato F, Venneri A. (2002). Rey-Osterrieth complex figure: normative values in an Italian population sample. Neurol Sci 22:443–447.
Carone M, Bertolotti G, Anchisi F, Zotti AM, Donner CF, Jones PW. (1999). Analysis of factors that characterize health impairment in patients with chronic respiratory failure. Quality of Life in Chronic Respiratory Failure Group. Eur Respir J 13:1293–1300.
Carver CS. (1997). You want to measure coping but your protocol’s too long: consider the brief COPE. Int J Behav Med 4:92–100.
O’Mara A, Rowland JH, Greenwell TN, Wiggs CL, Fleg J, Joseph L, et al.; NIH Medical Rehabilitation Coordinating Committee. (2017). National Institutes of Health Research Plan on Rehabilitation: NIH Medical Rehabilitation Coordinating Committee. Phys Ther 97:104–407.
Conti S, Bonazzi S, Laiacona M, Masina M, Coralli MV. (2015). Montreal Cognitive Assessment (MoCA)-Italian version: regression based norms and equivalent scores. Neurol Sci 36:209–214.
Di Carlo A, Baldereschi M, Lamassa M, Bovis F, Inzitari M, Solfrizzi V, et al.; Italian Longitudinal Study on Aging Working Group. (2016). Daily function as predictor of dementia in cognitive impairment, no dementia (CIND) and mild cognitive impairment (MCI): an 8-year follow-up in the ILSA study. J Alzheimers Dis 53:505–515.
Dunstan DA, Scott N. (2018). Assigning clinical significance and symptom severity using the Zung scales: levels of misclassification arising from confusion between index and raw scores. Depress Res Treat 2018:9250972.
Fava GA. (1983). Assessing depressive symptoms across cultures: Italian validation of the CES-D self-rating scale. J Clin Psychol 39:249–251.
Ferrer A, Costas J, Labad J, Salvat-Pujol N, Segalàs C, Urretavizcaya M, et al. (2018). FKBP5 polymorphisms and hypothalamic-pituitary-adrenal axis negative feedback in major depression and obsessive-compulsive disorder. J Psychiatr Res 104:227–234.
Fries GR, Gassen NC, Rein T. (2017). The FKBP51 glucocorticoid receptor co-chaperone: regulation, function, and implications in Health and Disease. Int J Mol Sci 18:E2614.
Fujii T, Ota M, Hori H, Hattori K, Teraishi T, Matsuo J, et al. (2014). The common functional FKBP5 variant rs1360780 is associated with altered cognitive function in aged individuals. Sci Rep 4:6696.
Graydon JE, Ross E. (1995). Influence of symptoms, lung function, mood, and social support on level of functioning of patients with COPD. Res Nurs Health 18:525–533.
Hubler TR, Scammell JG. (2004). Intronic hormone response elements mediate regulation of FKBP5 by progestins and glucocorticoids. Cell Stress Chaperones 9:243–252.
Ising M, Depping AM, Siebertz A, Lucae S, Unschuld PG, Kloiber S, et al. (2008). Polymorphisms in the FKBP5 gene region modulate recovery from psychosocial stress in healthy controls. Eur J Neurosci 28:389–398.
Kang JI, Chung HC, Jeung HC, Kim SJ, An SK, Namkoong K. (2012). FKBP5 polymorphisms as vulnerability to anxiety and depression in patients with advanced gastric cancer: a controlled and prospective study. Psychoneuroendocrinology 37:1569–1576.
Katz S, Downs TD, Cash HR, Grotz RC. (1970). Progress in development of the index of ADL. Gerontologist 10:20–30.
Lawton MP, Brody EM. (1969). Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 9:179–186.
Lee H, Yoon JY, Kim I, Jeong YH. (2013). The effects of personal resources and coping strategies on depression and anxiety in patients with chronic obstructive pulmonary disease. Heart Lung 42:473–479.
Lekman M, Laje G, Charney D, Rush AJ, Wilson AF, Sorant AJ, et al. (2008). The FKBP5-gene in depression and treatment response–an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Cohort. Biol Psychiatry 63:1103–1110.
Li Y, Cho MH, Zhou X. (2017). What do polymorphisms tell us about the mechanisms of COPD? Clin Sci (Lond) 131:2847–2863.
Magni E, Binetti G, Bianchetti A, Rozzini R, Trabucchi M. (1996). Mini-Mental State Examination: a normative study in Italian elderly population. Eur J Neurol 3:198–202.
Matosin N, Halldorsdottir T, Binder EB. (2018). Understanding the molecular mechanisms underpinning gene by environment interactions in psychiatric disorders: the FKBP5 model. Biol Psychiatry 83:821–830.
Mewes R, Rief W, Kenn K, Ried J, Stenzel N. (2016). Psychological predictors for health-related quality of life and disability in persons with chronic obstructive pulmonary disease (COPD). Psychol Health 31:470–486.
Miller MD, Paradis CF, Houck PR, Mazumdar S, Stack JA, Rifai AH, et al. (1992). Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale. Psychiatry Res 41:237–248.
Miravitlles M, Molina J, Quintano JA, Campuzano A, Pérez J, Roncero C; DEPREPOC study investigators. (2018). Depressive status explains a significant amount of the variance in COPD assessment test (CAT) scores. Int J Chron Obstruct Pulmon Dis 13:823–831.
Mlinac ME, Feng MC. (2016). Assessment of activities of daily living, self-care, and independence. Arch Clin Neuropsychol 31:506–516.
Montserrat-Capdevila J, Godoy P, Marsal JR, Ortega M, Pifarré J, Alsedà M, et al. (2018). Mental disorders in chronic obstructive pulmonary diseases. Perspect Psychiatr Care 54:398–404.
Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, et al. (2005). The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 53:695–699.
Pelleymounter LL, Moon I, Johnson JA, Laederach A, Halvorsen M, Eckloff B, et al. (2011). A novel application of pattern recognition for accurate SNP and indel discovery from high-throughput data: targeted resequencing of the glucocorticoid receptor co-chaperone FKBP5 in a Caucasian population. Mol Genet Metab 104:457–469.
Pierobon A, Ranzini L, Torlaschi V, Sini Bottelli E, Giardini A, Bruschi C, et al. (2018). Screening for neuropsychological impairment in COPD patients undergoing rehabilitation. PLoS One 13:e0199736.
Pollok J, van Agteren JE, Esterman AJ, Carson-Chahhoud KV. (2019). Psychological therapies for the treatment of depression in chronic obstructive pulmonary disease. Cochrane Database Syst Rev 3:CD012347.
Pooler A, Beech R. (2014). Examining the relationship between anxiety and depression and exacerbations of COPD which result in hospital admission: a systematic review. Int J Chron Obstruct Pulmon Dis 9:315–330.
Puteikis K, Mameniškienė R, Jurevičienė E. (2021). Neurological and psychiatric comorbidities in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 16:553–562.
Ragland MF, Benway CJ, Lutz SM, Bowler RP, Hecker J, Hokanson JE, et al. (2019). Genetic advances in chronic obstructive pulmonary disease. Insights from COPDGene. Am J Respir Crit Care Med 200:677–690.
Rao S, Yao Y, Ryan J, Li T, Wang D, Zheng C, et al. (2016). Common variants in FKBP5 gene and major depressive disorder (MDD) susceptibility: a comprehensive meta-analysis. Sci Rep 6:32687.
Roy A, Gorodetsky E, Yuan Q, Goldman D, Enoch MA. (2010). Interaction of FKBP5, a stress-related gene, with childhood trauma increases the risk for attempting suicide. Neuropsychopharmacology 35:1674–1683.
Russo P, Lococo F, Kisialiou A, Prinzi G, Lamonaca P, Cardaci V, et al. (2019a). Pharmacological management of chronic obstructive lung disease (COPD). Focus on mutations - part 1. Curr Med Chem 26:1721–1733.
Russo P, Prinzi G, Kisialiou A, Cardaci V, Stirpe E, Conti V, et al. (2017). Action plans and coping strategies in elderly COPD patients influence the result of pulmonary rehabilitation: an observational study. Eur J Phys Rehabil Med.
Russo P, Tomino C, Santoro A, Prinzi G, Proietti S, Kisialiou A, et al. (2019b). FKBP5 rs4713916: a potential genetic predictor of interindividual different response to inhaled corticosteroids in patients with chronic obstructive pulmonary disease in a real-life setting. Int J Mol Sci 20:2024.
Rybka J, Korte SM, Czajkowska-Malinowska M, Wiese M, Kędziora-Kornatowska K, Kędziora J. (2016). The links between chronic obstructive pulmonary disease and comorbid depressive symptoms: role of IL-2 and IFN-γ. Clin Exp Med 16:493–502.
Scarlata S, Antonelli-Incalzi R. (2011). Poor lung function and associated patterns of cognitive decline. Eur J Neurol 18:799–800.
Shafer AB. (2006). Meta-analysis of the factor structures of four depression questionnaires: Beck, CES-D, Hamilton, and Zung. J Clin Psychol 62:123–146.
Spruit MA, Wouters EFM. (2019). Organizational aspects of pulmonary rehabilitation in chronic respiratory diseases. Respirology 24:838–843.
Stoilkova-Hartmann A, Janssen DJ, Franssen FM, Wouters EF. (2015). Differences in change in coping styles between good responders, moderate responders and non-responders to pulmonary rehabilitation. Respir Med 109:1540–1545.
Strollo HC, Nouraie SM, Hoth KF, Riley CM, Karoleski C, Zhang Y, et al. (2021). Association of systemic inflammation with depressive symptoms in individuals with COPD. Int J Chron Obstruct Pulmon Dis 16:2515–2522.
Su VY, Hu LY, Yeh CM, Chiang HL, Shen CC, Chou KT, et al. (2017). Chronic obstructive pulmonary disease associated with increased risk of bipolar disorder. Chron Respir Dis 14:151–160.
Triest FJJ, Franssen FME, Reynaert N, Gaffron S, Spruit MA, Janssen D, et al. (2019). Disease-specific comorbidity clusters in COPD and accelerated aging. J Clin Med 8.
Uher R, Payne JL, Pavlova B, Perlis RH. (2014). Major depressive disorder in DSM-5: implications for clinical practice and research of changes from DSM-IV. Depress Anxiety 31:459–471.
Vaske I, Kenn K, Keil DC, Rief W, Stenzel NM. (2017). Illness perceptions and coping with disease in chronic obstructive pulmonary disease: effects on health-related quality of life. J Health Psychol 22:1570–1581.
Vermeer H, Hendriks-Stegeman BI, van der Burg B, van Buul-Offers SC, Jansen M. (2003). Glucocorticoid-induced increase in lymphocytic FKBP51 messenger ribonucleic acid expression: a potential marker for glucocorticoid sensitivity, potency, and bioavailability. J Clin Endocrinol Metab 88:277–284.
Vögele C, von Leupoldt A. (2008). Mental disorders in chronic obstructive pulmonary disease (COPD). Respir Med 102:764–773.
Zannas AS, Binder EB. (2014). Gene-environment interactions at the FKBP5 locus: sensitive periods, mechanisms and pleiotropism. Genes Brain Behav 13:25–37.
Zhang X, Clark AF, Yorio T. (2008). FK506-binding protein 51 regulates nuclear transport of the glucocorticoid receptor beta and glucocorticoid responsiveness. Invest Ophthalmol Vis Sci 49:1037–1047.
Zimmermann P, Brückl T, Nocon A, Pfister H, Binder EB, Uhr M, et al. (2011). Interaction of FKBP5 gene variants and adverse life events in predicting depression onset: results from a 10-year prospective community study. Am J Psychiatry 168:1107–1116.